Peter Kolchinsky‘s RA Capital Management has slightly raised its stake in Avexis Inc. (NASDAQ:AVXS), as per a new Form 13G with the Securities and Exchange Commission. The fund’s stake now consists of 1.89 million shares, which amass 6.8% of the company’s outstanding stock, while previously it’s position totaled 1.73 million shares, as reported in its 13F filing for the end of September.
AveXis, previously known as Biolife Cell Bank, is a company that works on discovering and producing various gene therapy treatments for people who suffer from neurological genetic disorders. Since the company started trading on February 12, its shares have gained an impressive 195.24%. In third quarter 2016 financial and operating results showed a loss per share of $0.87, missing the estimates of a loss per share of $0.69.
20 hedge funds from Insider Monkey’s database were bullish on Avexis Inc. (NASDAQ:AVXS) at the end of September, up by 10 from the previous quarter. The biggest position in the company was held by James E. Flynn’s Deerfield Management, worth around $92.2 million. Some other investors with similar enthusiasm contained Phill Gross and Robert Atchinson’s Adage Capital Management and Jeffrey Jay and David Kroin’s Great Point Partners.
Consequently, some big names have jumped into AveXis Inc. (NASDAQ:AVXS) headfirst. Marshall Wace LLP, led by Paul Marshall and Ian Wace, established the biggest position in AveXis. Marshall Wace LLP had $17.7 million invested in the company at the end of the quarter. Some other funds with new positions in the stock included Ken Griffin’s Citadel Investment Group, Israel Englander’s Millennium Management, and Benjamin A. Smith’s Laurion Capital Management.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|RA Capital Management||0||1,890,796||0||1,890,796||1,890,796||6.8%|
|RA Capital Healthcare Fund||0||1,476,084||0||1,476,084||1,476,084||5.3%|
Page 1 of 8 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of
(Amendment No. __)*
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
December 14, 2016
(Date of Event Which Requires Filing of
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).